Description
Servier India introduces ‘Ivosidenib'(Tibsovo®), in India, First-in-class Targeted Therapy in Oncology for Rare IDH1-Mutated AML and Cholangiocarcinoma.
Servier India, a subsidiary of the leading French pharmaceutical Servier Group, today announced the launch of Ivosidenib (Tibsovo®), an oral targeted therapy approved in the management of cancer patients with Acute Myeloid Leukemia (AML) and Cholangiocarcinoma, with an isocitrate dehydrogenase-1 (IDH1) mutation. Servier India received the approval on 14th May 2025, from Central Drugs Standard Control Organisation (CDSCO) for the import, sale, and distribution of the medication.
Ivosidenib, sold under the brand name Tibsovo, is an anti-cancer medication for the treatment of acute myeloid leukemia (AML) and cholangiocarcinoma. It is a small molecule inhibitor of isocitrate dehydrogenase-1 (IDH1), which is mutated in several forms of cancer. Ivosidenib is an isocitrate dehydrogenase-1 inhibitor that works by decreasing abnormal production of the oncometabolite 2-hydroxyglutarate (2-HG), leading to differentiation of malignant cells.
Internationally, Ivosidenib has already received regulatory approvals in more than 42 countries, including the USA, Europe, China, UAE, and South Korea. In the United States, the US FDA approved it in 2019 as a monotherapy and later in May 2022 as a combination treatment with Azacitidine for patients aged 75 and above, or those who cannot tolerate intensive chemotherapy. The European Medical Agency (EMA) gave its approval in May 2023 for use in patients who are not fit for standard induction chemotherapy.
In India, the process moved forward in April 2025, when the Subject Expert Committee (SEC) gave a positive recommendation for Ivosidenib. Following this, the DCGI granted approval for the marketing authorization in May 2025
Who is the CFA, distributor, and retailer for TIBSOVO (ivosidenib) Tablets in India?
Aark Pharmaceuticals is an authorized distributor, CFA (Carry and Forward Agent), and retailer for TIBSOVO (ivosidenib) Tablets in India. It is marketed by Servier India Pvt. Ltd.. Aark claims to provide 100% authentic, cold-chain managed medicines. Aark supplies a wide range of Servier India Pvt. Ltd. products, including advanced cancer treatments.
The company serves hospitals, clinics, and patients across India, including major cities like Bangalore, Surat, Kolkata, Indore, Nagpur, Patiala, Srinagar, Ahmedabad, Osmanabad, Mumbai, Pune, Amaravati, Itanagar, Dispur, Patna, Raipur, Panaji, Gandhinagar, Chandigarh, Shimla, Ranchi, Bengaluru, Thiruvananthapuram, Imphal, Shillong, Aizawl, Kohima, Bhubaneswar, Jaipur, Gangtok, Chennai, Hyderabad, Coimbatore, Kochi, Kollam, Agartala, Lucknow, Dehradun, Gairsain, Aizawal, Aurangabad, Barshi, Karungapally, Pondichery, Punjab, Delhi, New Delhi, Agra, Kanpur, Gurugram, Alwar, Mathura, Panipat, Faridabad, Noida, Sonipat, Rohtak, Karnal, Ambala, Ghaziabad, Wardha, Bhopal, Manipur, Mizoram, Sikkim, Tripura, Arunachal, Meghalaya, Nagaland, Pasighat, Cachar, Dibrugarh, Kamrup.
How much do TIBSOVO Tablets cost in Delhi, India?
Prices may vary based on your prescribed treatment plan. For accurate and the most cost-effective pricing on your prescription-recommended product, please contact Aark Pharmaceuticals
Contact Person: Ms. Himanshi
Address: S-14, Ground & Ist Floor, Green Park Extn., New Delhi-110016.
Do you offer any discounts?
Yes. Based on availability, prices may vary based on your prescribed treatment plan. Please ask for the best current price.
Prior to consuming any medications, including ivosidenib Tablets, it is advisable to seek guidance from a medical professional regarding its therapeutic advantages, usage instructions, and potential side effects.
NEWS / UPDATES
- Servier India introduces ‘Ivosidenib’ (Tibsovo®) in India
- Servier India introduces ‘Ivosidenib'(Tibsovo®), in India, First-in-class Targeted Therapy in Oncology for Rare IDH1-Mutated AML and Cholangiocarcinoma
- Servier India launches IDH1-targeted therapy Ivosidenib for AML and Cholangiocarcinoma
- Servier India Launches Tibsovo® for Targeted Cancer Treatment in AML and Cholangiocarcinoma
Written By
Mr. Sandeep Tomar (D. pharma)
Last updated
14 April 2026 AM (IST)
